Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Niki Karachaliou
Systemic Treatment in EGFR-ALK NSCLC Patients: Second Line Therapy and Beyond
Expert Review of Anticancer Therapy
Oncology
Pharmacology
‹
1
2
Related publications
P3.01-86 Treatment Outcomes With Reduced Frequency of Nivolumab Dosing as Second-Line Therapy in Patients With Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
First-Line Osimertinib in Patients With Treatment-Naive Somatic or Germline EGFR T790M–Mutant Metastatic NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Comparison of EGFR-TKI and Chemotherapy in the First-Line Treatment of Advanced EGFR Mutation-Positive NSCLC
Neoplasma
Cancer Research
MS18.04 Retreatment With Platinum and Etoposide and Treatment Beyond Second Line
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
First-Line Treatment in NSCLC Harboring EGFR Common Mutations: EGFR TKI in Monotherapy or in Combination With Anti-Vegf?
Expert Review of Anticancer Therapy
Oncology
Pharmacology
P013 Anti-Pd-1 Combination Therapy as Second Line Treatment or Beyond in Patients With Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Letter to the Editor Concerning First-Line Therapy With Afatinib – An Irreversible EGFR TKI and Overall Survival of NSCLC Patients With EGFR Gene Mutations
Wspolczesna Onkologia
Oncology
Radiology
Nuclear Medicine
Imaging
P3.01-110 Defining Aggressive Disease in Patients With Advanced NSCLC Receiving Second-Line Treatment: A Systematic Review
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Anti-Angiogenic Drugs for Second-Line Treatment of NSCLC Patients: Just New Pawns on the Chessboard?
Expert Opinion on Biological Therapy
Drug Discovery
Clinical Biochemistry
Pharmacology
